Neurocrine Biosciences Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2009 | $-53.1M | $-53.1M | $35.0K | $5.5M |
| FY2010 | $49.9M | $49.6M | $315.0K | $3.1M |
| FY2011 | $-698.0K | $-1.4M | $750.0K | $2.9M |
| FY2012 | $-35.3M | $-36.3M | $971.0K | $5.5M |
| FY2013 | $-29.6M | $-30.2M | $545.0K | $6.8M |
| FY2014 | $-47.1M | $-48.8M | $1.6M | $10.4M |
| FY2015 | $-38.0M | $-39.9M | $1.9M | $28.4M |
| FY2016 | $-106.2M | $-110.3M | $4.1M | $28.5M |
| FY2017 | $-94.3M | $-101.3M | $6.9M | $42.5M |
| FY2018 | $101.4M | $76.6M | $24.8M | $58.1M |
| FY2019 | $147.0M | $132.3M | $14.7M | $75.3M |
| FY2020 | $228.5M | $217.6M | $10.9M | $100.0M |
| FY2021 | $256.5M | $233.1M | $23.4M | $134.2M |
| FY2022 | $339.4M | $322.9M | $16.5M | $173.1M |
| FY2023 | $389.9M | $361.6M | $28.3M | $194.3M |
| FY2024 | $595.4M | $557.2M | $38.2M | $195.5M |
| FY2025 | $782.7M | $748.7M | $34.0M | $217.9M |